2020
DOI: 10.1097/cco.0000000000000668
|View full text |Cite
|
Sign up to set email alerts
|

CD19-directed CAR T-cell therapy in B-cell NHL

Abstract: Purpose of review CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials. Recent findings For decades, attempts at improvement of the poor prognosis of patients with R/R large B-cell lymphoma with new treatment regi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
25
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 28 publications
(25 citation statements)
references
References 61 publications
0
25
0
Order By: Relevance
“… 4 After being transduced, the CAR-T cells are reinjected by intravenous infusion. 5 The morphologic and immunophenotypic description of CAR-T cells observed in residual cells of CAR-T cells infusion bag has just been described by Galli et al in this journal. 6 Here we confirm their findings in the peripheral blood (PB) and report about our experience of CAR-T cells automated and microscopic detection and immune monitoring.…”
mentioning
confidence: 75%
“… 4 After being transduced, the CAR-T cells are reinjected by intravenous infusion. 5 The morphologic and immunophenotypic description of CAR-T cells observed in residual cells of CAR-T cells infusion bag has just been described by Galli et al in this journal. 6 Here we confirm their findings in the peripheral blood (PB) and report about our experience of CAR-T cells automated and microscopic detection and immune monitoring.…”
mentioning
confidence: 75%
“…B cell targeting using CAR-T cell therapy focuses on B cell markers CD19, CD20 and B cell maturation antigen (BCMA) as antigenic targets, for instance, in the field of B cell leukaemia [ 85 ], B cell lymphoma [ 86 , 87 ] and multiple myeloma [ 88 ]. Next to the oncological field, B cell overactivation has also been implicated in the field of autoimmunity, where dysregulated B cell activation leads to an antibody-mediated targeting of healthy own body tissue.…”
Section: Cell-based Therapiesmentioning
confidence: 99%
“…CAR-T cell therapy has demonstrated unprecedented response rates in patients with B cell lymphoma since the first approval of CD19-targeted CAR-T cells in the USA (1,(3)(4)(5). However, along with the remarkable achievements of CAR-T cell therapy, many systemic toxicities, such as cytokine release syndrome (CRS) and neurotoxicity, have also been frequently reported (2,(6)(7)(8). Additionally, the complex manufacturing process of CAR-T cells limits the broader applications of this therapeutic method as a standard clinical treatment (2,(9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%